Headlines:
Tag: Pharmaceuticals
UCB Completes the Acquisition of Ra Pharmaceuticals – to Deliver Differentiated Therapies to Patients

UCB Completes the Acquisition of Ra Pharmaceuticals – to Deliver Differentiated Therapies to Patients

April 7, 2020 Economie

- The transaction, which was announced October 10, 2019, will enhance UCB's potential to be a leader in myasthenia gravis by adding zilucoplan, a peptide inhibitor of ...

Lees verder
Arena Pharmaceuticals Highlights Strategic Plan Driving Near and Long-term Growth with Eight Ph 2 and Ph 3 Data Readouts in 2020-21 and One New I

Arena Pharmaceuticals Highlights Strategic Plan Driving Near and Long-term Growth with Eight Ph 2 and Ph 3 Data Readouts in 2020-21 and One New I

January 7, 2020 Economie

- Initiation of etrasimod Ph 2/3 program in Crohn's disease (CD) - Two additional Ph 2 etrasimod development programs in eosinophilic esophagitis (EoE) and alopecia areata ...

Lees verder
Centrient Pharmaceuticals: Kans om Wereldwijd Antibiotica Productieafval Aan te Pakken

Centrient Pharmaceuticals: Kans om Wereldwijd Antibiotica Productieafval Aan te Pakken

June 19, 2019 Economie

ROTTERDAM, Nederland, 18 juni 2019 /PRNewswire/ -- Terwijl leiders samenkomen op de International Ministerial Conference over antimicrobiële resistentie (AMR), roepen ...

Lees verder
Britannia Pharmaceuticals Ltd: Phase 3 TOLEDO Study Shows Apomorphine Infusion Provides Effective Relief of Persistent Motor Fluctuations in Park

Britannia Pharmaceuticals Ltd: Phase 3 TOLEDO Study Shows Apomorphine Infusion Provides Effective Relief of Persistent Motor Fluctuations in Park

August 4, 2018 Economie

LONDON, August 3, 2018 /PRNewswire/ -- Britannia Pharmaceuticals Ltd has announced publication of the results of the double-blind phase of the TOLEDO study in Lancet ...

Lees verder
Foresee Pharmaceuticals Announces Results from a Phase 1 Clinical Study, Highlighting Promising Safety, Tolerability and Pharmacokinetic Profile

Foresee Pharmaceuticals Announces Results from a Phase 1 Clinical Study, Highlighting Promising Safety, Tolerability and Pharmacokinetic Profile

July 26, 2018 Economie

TAIPEI, Taiwan, July 26, 2018 /PRNewswire/ -- Foresee Pharmaceuticals Co., Ltd. (6576.TWO) ("Foresee"), announced today that it has successfully completed a Phase 1 multiple ...

Lees verder
GW Pharmaceuticals and its U.S. Subsidiary Greenwich Biosciences Announce Publication of Landmark Epidiolex® (Cannabidiol) Study in The Lancet

GW Pharmaceuticals and its U.S. Subsidiary Greenwich Biosciences Announce Publication of Landmark Epidiolex® (Cannabidiol) Study in The Lancet

January 28, 2018 Economie

LONDON and CARLSBAD, California, January 24, 2018 /PRNewswire/ -- - First well-controlled clinical study of cannabidiol in Lennox-Gastaut syndrome, a rare, severe, form of ...

Lees verder
GW Pharmaceuticals Submits Marketing Authorisation Application in Europe for Epidiolex® (cannabidiol) in the Treatment of Lennox-Gastaut Syndrome

GW Pharmaceuticals Submits Marketing Authorisation Application in Europe for Epidiolex® (cannabidiol) in the Treatment of Lennox-Gastaut Syndrome

December 30, 2017 Economie

LONDON, December 29, 2017 /PRNewswire/ -- GW Pharmaceuticals plc , a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from ...

Lees verder
Foresee Pharmaceuticals Announces Results from Phase 1 Clinical Studies

Foresee Pharmaceuticals Announces Results from Phase 1 Clinical Studies

December 4, 2017 Economie

Highlighting Promising Safety, Tolerability and Pharmacokinetic Profile of FP-025, a Selective MMP-12 Inhibitor. TAIPEI, Taiwan, Dec. 4, 2017 /PRNewswire/ -- Foresee ...

Lees verder
Foresee Pharmaceuticals Announces CEO Appointment

Foresee Pharmaceuticals Announces CEO Appointment

July 31, 2017 Economie

TAIPEI, Taiwan, July 31, 2017 /PRNewswire/ -- Foresee Pharmaceuticals Co., Ltd. (6576.TWO) ("Foresee"), announced today the appointment of Dr. Lawrence Gan to the position of ...

Lees verder
Debiopharm International SA and Arbor Pharmaceuticals, LLC Announce U.S. FDA Approval for Triptodur(TM), Triptorelin 6-month Formulation, in the

Debiopharm International SA and Arbor Pharmaceuticals, LLC Announce U.S. FDA Approval for Triptodur(TM), Triptorelin 6-month Formulation, in the

June 30, 2017 Economie

LAUSANNE, Switzerland and ATLANTA, June 30, 2017 /PRNewswire/ -- Triptodur(TM), (triptorelin) for extended release injectable suspension, has been shown to arrest or reverse ...

Lees verder
Nieuwe berichten
BizPress.nl